Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Open-Label Surufatinib in European Patients With NET
NCT04579679 · Hutchmed · PHASE2 · terminated · last registry update 2025-07-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | – | Registry record, Hutchmed |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FGFR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-23Phase 3 first posted: Innovent Biologics (Suzhou) Co. Ltd., IBI363 + bevacizumab + Investigator's choice of therapy (NCT07722494)
- 2026-07-22Results posted on the registry: Amgen, Sotorasib + Panitumumab (NCT05198934)
- 2026-07-20Results posted on the registry: Academic and Community Cancer Research United, Durvalumab + Regorafenib (NCT05194293)
- 2026-07-17Phase 3 first posted: Taiho Pharmaceutical Co., Ltd., Futibatinib + Zimberelimab (NCT07710885)
- 2026-07-09Results posted on the registry: Eli Lilly and Company, Pegilodecakin + Paclitaxel or Docetaxel and Carboplatin or Cisplatin (NCT02009449)
- 2026-07-06Results posted on the registry: Syndax Pharmaceuticals, Revumenib + Chemotherapy (NCT05731947)
- 2026-07-06Also stopped (terminated): Syndax Pharmaceuticals, Revumenib + Chemotherapy (NCT05731947)
- 2026-06-16Results posted on the registry: University of Southern California, Pembrolizumab + Regorafenib (NCT03657641)
- 2026-06-15Also stopped (withdrawn): University of Miami, Regorafenib (NCT06902246)
- 2026-06-11Also stopped (terminated): Changhai Hospital, Surufatinib + Placebo (NCT06158516)
- 2026-06-10Results posted on the registry: Australasian Gastro-Intestinal Trials Group, Regorafenib + Nivolumab (NCT04879368)
- 2026-04-30Results posted on the registry: Icahn School of Medicine at Mount Sinai, Nintedanib + Placebo (NCT04619680)
- 2026-04-14Results posted on the registry: National Cancer Institute (NCI), Ensartinib + Erdafitinib (NCT03155620)
- 2026-04-14Also stopped (terminated): Institut Claudius Regaud, Pazopanib (NCT01642017)
- 2026-04-09Phase 3 first posted: Haisco Pharmaceutical Group Co., Ltd., HSK44459 + HSK44459 (NCT07519070)
- 2026-04-08Results posted on the registry: National Cancer Institute (NCI), Olaparib + Pazopanib (NCT05432791)
- 2026-04-01Phase 3 first posted: The First Hospital of Jilin University, Experimental Group + Control group (NCT07505472)
- 2026-03-27Also stopped (terminated): M.D. Anderson Cancer Center, Futibatinib + Pembrolizumab (NCT05036681)
- 2026-03-19Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., TQB2102 Injection + Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets (NCT07483684)
- 2026-03-11Also stopped (withdrawn): M.D. Anderson Cancer Center, Regorafenib + Lorigerlimab (NCT07137390)
- 2026-03-09Also stopped (terminated): Translational Research in Oncology, Regorafenib in combination with pembrolizumab (NCT04777851)
- 2026-03-05Results posted on the registry: Wake Forest University Health Sciences, Regorafenib (NCT04327700)
- 2026-03-05Also stopped (terminated): Wake Forest University Health Sciences, Regorafenib (NCT04327700)
- 2026-03-04Results posted on the registry: Boehringer Ingelheim, Nintedanib (Ofev®) (NCT05285982)
- 2026-02-27Phase 3 first posted: Tianjin Medical University Cancer Institute and Hospital, surufatinib + gemcitabine + nab-paclitaxel + gemcitabine + nab-paclitaxel (NCT07436741)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision